Novartis conducts safety study of Iptacopan in PNH patients using registry data
Novartis is conducting a post-authorization safety study of Iptacopan in adult PNH patients using data from the IPIG PNH registry.
Asset / Drug
Drug and asset intelligence for Iptacopan with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.